DK1699462T3 - Kombination af [6R]-methylentetrahydrofolat med multitarget-antifolater med henblik på at mindske deres toxicitet ved cancerbehandling - Google Patents

Kombination af [6R]-methylentetrahydrofolat med multitarget-antifolater med henblik på at mindske deres toxicitet ved cancerbehandling

Info

Publication number
DK1699462T3
DK1699462T3 DK04809128T DK04809128T DK1699462T3 DK 1699462 T3 DK1699462 T3 DK 1699462T3 DK 04809128 T DK04809128 T DK 04809128T DK 04809128 T DK04809128 T DK 04809128T DK 1699462 T3 DK1699462 T3 DK 1699462T3
Authority
DK
Denmark
Prior art keywords
tetrahydrofolate
multitarget
methylenetetrahydrofolate
antifolates
toxicity
Prior art date
Application number
DK04809128T
Other languages
English (en)
Inventor
Bengt Gustavsson
Goeran Carlsson
Original Assignee
Isofol Medical Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isofol Medical Ab filed Critical Isofol Medical Ab
Application granted granted Critical
Publication of DK1699462T3 publication Critical patent/DK1699462T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Silicates, Zeolites, And Molecular Sieves (AREA)
DK04809128T 2003-12-22 2004-12-22 Kombination af [6R]-methylentetrahydrofolat med multitarget-antifolater med henblik på at mindske deres toxicitet ved cancerbehandling DK1699462T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0303526A SE0303526D0 (sv) 2003-12-22 2003-12-22 Chemotherapeutic agents
PCT/SE2004/001955 WO2005060973A1 (en) 2003-12-22 2004-12-22 Reduction of toxicity of multi-targeting antifolates

Publications (1)

Publication Number Publication Date
DK1699462T3 true DK1699462T3 (da) 2010-11-08

Family

ID=30768841

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04809128T DK1699462T3 (da) 2003-12-22 2004-12-22 Kombination af [6R]-methylentetrahydrofolat med multitarget-antifolater med henblik på at mindske deres toxicitet ved cancerbehandling

Country Status (14)

Country Link
US (3) US20070249613A1 (da)
EP (1) EP1699462B1 (da)
JP (2) JP5043441B2 (da)
AT (1) ATE476996T1 (da)
CA (1) CA2550298C (da)
CY (1) CY1110859T1 (da)
DE (1) DE602004028654D1 (da)
DK (1) DK1699462T3 (da)
ES (2) ES2349929T3 (da)
PL (1) PL1699462T3 (da)
PT (1) PT1699462E (da)
SE (1) SE0303526D0 (da)
SI (1) SI1699462T1 (da)
WO (1) WO2005060973A1 (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0303526D0 (sv) 2003-12-22 2003-12-22 Biofol Ab Chemotherapeutic agents
EP2617422A1 (en) 2012-01-20 2013-07-24 Isofol Medical AB Anti-tumor activity of reduced folates like methylene-tetrahydrofolate, tetrahydrofolate or methyl-tetrahydrofolate
EP2617421A1 (en) 2012-01-20 2013-07-24 Isofol Medical AB Tetrahydrofolates in combination with EGFR-inhibitors in the use of treating cancer
KR101673979B1 (ko) * 2012-04-13 2016-11-08 리안윤강 진강 해신 파머수티컬 코. 엘티디. 화합물 jk12a 및 그 제조
NL2019147B1 (en) 2017-06-29 2019-01-14 D O R C Dutch Ophthalmic Res Center International B V A foot pedal control unit

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376658A (en) 1990-05-11 1994-12-27 University Of Southern California 5,10-methylene-tetrahydrofolate as a modulator of a chemotherapeutic agent
CA2082811C (en) * 1990-05-11 2004-11-16 Colin P. Spears 5,10-methylene-tetrahydrofolate as a modulator of a chemotherapeutic agent
CH693255A5 (de) * 1997-06-13 2003-05-15 Eprova Ag Verwendung von Tetrahydrofolaten in der natürlichenstereoisomeren Form zur Herstellung einer pharmazeutischenZubereitung geeignet zur Beeinflussung des Homocystein-Spiegels.
US6921667B2 (en) * 2003-03-07 2005-07-26 Prometheus Laboratories, Inc. Methods for direct detection of individual methotrexate metabolites
SE0303526D0 (sv) 2003-12-22 2003-12-22 Biofol Ab Chemotherapeutic agents

Also Published As

Publication number Publication date
WO2005060973A1 (en) 2005-07-07
US20100311762A1 (en) 2010-12-09
JP2007515482A (ja) 2007-06-14
SE0303526D0 (sv) 2003-12-22
DE602004028654D1 (de) 2010-09-23
SI1699462T1 (sl) 2010-12-31
JP5043441B2 (ja) 2012-10-10
PL1699462T3 (pl) 2011-04-29
EP1699462B1 (en) 2010-08-11
US20150328218A1 (en) 2015-11-19
EP1699462A1 (en) 2006-09-13
CY1110859T1 (el) 2015-06-10
PT1699462E (pt) 2010-11-05
ES2349930T3 (es) 2011-01-13
CA2550298A1 (en) 2005-07-07
US20070249613A1 (en) 2007-10-25
ATE476996T1 (de) 2010-08-15
JP2012087130A (ja) 2012-05-10
CA2550298C (en) 2013-05-28
US9138435B2 (en) 2015-09-22
US9585888B2 (en) 2017-03-07
ES2349929T3 (es) 2011-01-13

Similar Documents

Publication Publication Date Title
NO20040547L (no) Amino-ftalazinonderivater aktive som kinaseinhibitorer, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende disse.
TW200716631A (en) Pyrido[2,3-d]pyrimidines useful as HCV inhibitors, and methods for the preparation thereof
SE0300010D0 (sv) Novel Compounds
NO20070656L (no) 2,4,6-Trisubstituerte pyrimidiner som fosfotidylinositol-(PI)-3-kinaseinhibitorer og disses anvendelse ved behandling av kreft
WO2007044407A3 (en) Pyrazolo (1 , 5a) pyrimidines as protein kinase inhibitors
NO20075046L (no) Gastroresistente farmasoytiske formuleringer inneholdende rifaximin
WO2006091568A3 (en) Hydroxyalkyl substituted imidazonaphthyridines
IL199151A (en) Pyrimidine derivatives, their pharmaceutical preparations, their use in cancer treatment and their kits
TW200744602A (en) Administration of dipeptidyl peptidase inhibitors
WO2007064968A3 (en) Stable pharmaceutical compositions of 5,10 methylenetetrahydrofolate
WO2005105094A3 (en) Cancer treatment method
NO20082376L (no) Farmasoytiske sammensetninger
BRPI0518993A2 (pt) composto ou um sal, solvato ou Éster farmaceuticamente aceitÁvel do mesmo, composiÇço farmacÊutica, e, uso de um composto
CY1110859T1 (el) Συνδυασμος [6r]-meθyλenotetpayδpοφολikoy με πολυ-στοχοθετικα αντιφολικα για να μειωνεται τοξικοτητα αυτων ενω θεραπευεται καρκινος
ATE500831T1 (de) Krebsbehandlungsverfahren
ATE359791T1 (de) Pyrimidin-2,4-dion-derivate als matrix- metalloproteinase-hemmer
TW200833699A (en) P-toluene sulfonic acid salt of 5-amino-3-(2'-O-acetyl-3'-deoxy-β-D-ribofuranosyl)-3H-thiazolo[4,5-d]pyrimidine-2-one and methods for preparation
YU64602A (sh) Smeša koja se sastoji od kamptotecina i derivata pirimidina za terapiju kancera
WO2005009348A3 (en) Substituted purine derivatives
NO20054723L (no) Behandling av proliferative sykdommer med epofilonderivater og straling
WO2007043094A3 (en) 6-vinyl pyrimidine and pyrimidinone derivatives and the use thereof
WO2004108094A3 (en) Sulfonamide-substituted chalcone derivatives and their use to treat diseases
TW200716123A (en) Pteridines useful as HCV inhibitors and methods for the preparation thereof
WO2004011005A3 (en) Antimicrobial 2, 4-diamino-pteridine derivatives
MXPA04005901A (es) Composiciones a base de taxano y metodos de uso.